One Wealth Advisors LLC Reduces Stock Holdings in Zymeworks Inc. (NYSE:ZYME)

One Wealth Advisors LLC lowered its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 42.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 13,979 shares of the company’s stock after selling 10,366 shares during the quarter. One Wealth Advisors LLC’s holdings in Zymeworks were worth $205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. FMR LLC increased its holdings in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after buying an additional 1,525 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Zymeworks in the 3rd quarter worth $47,000. nVerses Capital LLC bought a new position in Zymeworks in the 3rd quarter worth $79,000. China Universal Asset Management Co. Ltd. lifted its position in Zymeworks by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,665 shares of the company’s stock valued at $171,000 after purchasing an additional 5,359 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Zymeworks by 13.2% during the second quarter. The Manufacturers Life Insurance Company now owns 22,695 shares of the company’s stock valued at $193,000 after purchasing an additional 2,653 shares during the period. Institutional investors own 92.89% of the company’s stock.

Zymeworks Stock Up 0.7 %

ZYME opened at $14.70 on Tuesday. The company has a fifty day moving average of $14.10 and a 200 day moving average of $13.06. Zymeworks Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $17.70.

Insider Buying and Selling at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc acquired 16,692 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average cost of $14.38 per share, with a total value of $240,030.96. Following the purchase, the director now directly owns 14,720,931 shares of the company’s stock, valued at approximately $211,686,987.78. This represents a 0.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul Andrew Moore sold 21,200 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $316,304.00. Following the sale, the insider now owns 14,741 shares in the company, valued at $219,935.72. This represents a 58.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 603,539 shares of company stock valued at $8,384,708 and sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company’s stock.

Analyst Ratings Changes

ZYME has been the topic of several recent research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of Zymeworks in a research note on Friday, November 22nd. Leerink Partners raised shares of Zymeworks from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $10.00 to $25.00 in a report on Thursday, November 7th. JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a research note on Monday, December 16th. Citigroup lifted their target price on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Finally, Stifel Nicolaus increased their price target on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.17.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.